DihydrobaicaleinCAS# 35683-17-1 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 35683-17-1 | SDF | Download SDF |
| PubChem ID | 14135323 | Appearance | Powder |
| Formula | C15H12O5 | M.Wt | 272.3 |
| Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2S)-5,6,7-trihydroxy-2-phenyl-2,3-dihydrochromen-4-one | ||
| SMILES | C1C(OC2=CC(=C(C(=C2C1=O)O)O)O)C3=CC=CC=C3 | ||
| Standard InChIKey | GPDJGLOROGNHJD-NSHDSACASA-N | ||
| Standard InChI | InChI=1S/C15H12O5/c16-9-6-11(8-4-2-1-3-5-8)20-12-7-10(17)14(18)15(19)13(9)12/h1-5,7,11,17-19H,6H2/t11-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Dihydrobaicalein is a natural product from Scutellaria baicalensis Georgi. |
| Structure Identification | Japanese Journal of Pharmacognosy, 1988 , 42 :204-7.Studies on the Nepalese Crude Drugs (X) : On the Flavonoid and the Stilbene Constituents of the Leaves of Scutellaria scandens BUCH. -HAM. ex D. DON[Reference: WebLink]
|
Dihydrobaicalein Dilution Calculator
Dihydrobaicalein Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.6724 mL | 18.3621 mL | 36.7242 mL | 73.4484 mL | 91.8105 mL |
| 5 mM | 0.7345 mL | 3.6724 mL | 7.3448 mL | 14.6897 mL | 18.3621 mL |
| 10 mM | 0.3672 mL | 1.8362 mL | 3.6724 mL | 7.3448 mL | 9.1811 mL |
| 50 mM | 0.0734 mL | 0.3672 mL | 0.7345 mL | 1.469 mL | 1.8362 mL |
| 100 mM | 0.0367 mL | 0.1836 mL | 0.3672 mL | 0.7345 mL | 0.9181 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Deoxylapachol
Catalog No.:BCN5299
CAS No.:3568-90-9
- Fmoc-Leu-OH
Catalog No.:BCC3509
CAS No.:35661-60-0
- Fmoc-Phe-OH
Catalog No.:BCC3535
CAS No.:35661-40-6
- Fmoc-Ala-OH
Catalog No.:BCC3034
CAS No.:35661-39-3
- SB525334
Catalog No.:BCC2531
CAS No.:356559-20-1
- SB-505124 hydrochloride
Catalog No.:BCC1930
CAS No.:356559-13-2
- NSC 3852
Catalog No.:BCC2423
CAS No.:3565-26-2
- Benzbromarone
Catalog No.:BCC4634
CAS No.:3562-84-3
- Mesuaxanthone A
Catalog No.:BCN5298
CAS No.:3561-81-7
- CP 20961
Catalog No.:BCC6063
CAS No.:35607-20-6
- N-Desethyl Sunitinib
Catalog No.:BCC1792
CAS No.:356068-97-8
- Toceranib
Catalog No.:BCC2005
CAS No.:356068-94-5
- Questinol
Catalog No.:BCN7443
CAS No.:35688-09-6
- Valerenic acid
Catalog No.:BCC7546
CAS No.:3569-10-6
- Naloxone HCl
Catalog No.:BCC4612
CAS No.:357-08-4
- Brucine
Catalog No.:BCN2390
CAS No.:357-57-3
- Galantamine
Catalog No.:BCN2868
CAS No.:357-70-0
- Albaspidin AA
Catalog No.:BCN5300
CAS No.:3570-40-9
- Moslosooflavone
Catalog No.:BCN5301
CAS No.:3570-62-5
- Pemetrexed disodium hemipenta hydrate
Catalog No.:BCC1844
CAS No.:357166-30-4
- Tropanyl trans-cinnamate
Catalog No.:BCN1931
CAS No.:35721-92-7
- BMS-378806
Catalog No.:BCC4505
CAS No.:357263-13-9
- Hygrophylline
Catalog No.:BCN2116
CAS No.:3573-82-8
- Cynaropicrin
Catalog No.:BCC8161
CAS No.:35730-78-0
7-O-Methylwogonin from Scutellaria baicalensis Disturbs Mitotic Progression by Inhibiting Plk1 Activity in Hep3B Cells.[Pubmed:30199903]
Planta Med. 2019 Feb;85(3):217-224.
Polo-like kinase 1, a mitotic Ser/Thr kinase, has emerged as a molecular target for the development of anticancer drugs. In this study, we found that polo-like kinase 1 activity was inhibited by 7-O-methylwogonin and related flavones, including baicalein, Dihydrobaicalein, and viscidulin II, isolated from Scutellaria baicalensis. Although Dihydrobaicalein exhibited the highest polo-like kinase 1 inhibitory activity among the four compounds, it also inhibited other kinases, such as vaccinia-related kinase 2 and polo-like kinase 2. Baicalein and viscidulin II also showed low selectivity to polo-like kinase 1 since they inhibited polo-like kinase 3 and polo-like kinase 2, respectively. However, 7-O-methylwogonin exhibited selective polo-like kinase 1 inhibitory activity, as evidenced from in vitro kinase assays based on fluorescence resonance energy transfer assays and ADP-Glo kinase assays. In addition, examination of mitotic morphology and immunostaining using specific antibodies for the mitotic markers, p-histone H3 and mitotic protein monoclonal 2, in Hep3B cells showed that 7-O-methylwogonin treatment increased mitotic cell populations due to inhibition of mitotic progression as a result of polo-like kinase 1 inhibition. The pattern of 7-O-methylwogonin-induced mitotic arrest was similar to that of BI 2536, a specific polo-like kinase 1 inhibitor. Thus, it was suggested that 7-O-methylwogonin disturbed mitotic progression by inhibiting polo-like kinase 1 activity. These data suggest that 7-O-methylwogonin, a polo-like kinase 1 inhibitor, may be a useful anticancer agent because of its polo-like kinase 1 selectivity and effectiveness.
